NX Development Corp. (NXDC) Launches FDA-Approved Gleolan™ (aminolevulinic acid HCl) for Enhanced Visualization of High-Grade Gliomas (including Glioblastomas)
October 03, 2018 14:50 ET
|
NX Development Corp.
Lexington, KY, Oct. 03, 2018 (GLOBE NEWSWIRE) -- NX Development Corp. (NXDC), a life sciences company, today announced the U.S. commercial launch of its flagship product Gleolan™ (aminolevulinic...
Profiling Brain Cancers for More Targeted Treatments
December 22, 2017 09:03 ET
|
The Jackson Laboratory
Farmington, Conn., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Roel Verhaak, Ph.D., is not beholden to the status quo. After all, his field, computational biology, didn’t exist, at least not formally, when he...
MRI Interventions to Exhibit its ClearPoint Neuro Intervention System at AANS 2014 Annual Meeting
April 03, 2014 08:10 ET
|
ClearPoint Neuro, Inc.
IRVINE, Calif., April 3, 2014 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) today announced that its ClearPoint® Neuro Intervention System will be on exhibit at the 2014 Annual Meeting...
Importance of Real-Time MRI Guidance in Delivery of Toca 511 Gene Therapy Directly to High Grade Glioma Presented at Annual Society for Neuro-Oncology Scientific Meeting
December 03, 2013 08:00 ET
|
ClearPoint Neuro, Inc.
IRVINE, Calif., Dec. 3, 2013 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) today announced the presentation of clinical data demonstrating the precision of MRI-guided delivery of the...